Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Godsey & Gibb Inc.

Godsey & Gibb Inc. lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,718 shares of the medical research company’s stock after purchasing an additional 2,041 shares during the period. Godsey & Gibb Inc.’s holdings in Amgen were worth $16,868,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the stock. Capital Performance Advisors LLP purchased a new stake in Amgen during the third quarter valued at about $25,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen during the second quarter valued at approximately $30,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the 3rd quarter worth $29,000. Matrix Trust Co purchased a new position in Amgen in the third quarter valued at about $36,000. Finally, Livelsberger Financial Advisory acquired a new stake in shares of Amgen during the third quarter worth approximately $56,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AMGN shares. Bank of America reissued an “underperform” rating and set a $256.00 price target on shares of Amgen in a research report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Redburn Partners decreased their price target on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Finally, Barclays boosted their target price on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Amgen has an average rating of “Hold” and an average target price of $314.91.

Amgen Stock Performance

Shares of Amgen stock opened at $268.94 on Thursday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock has a market cap of $144.56 billion, a price-to-earnings ratio of 34.44, a P/E/G ratio of 2.91 and a beta of 0.56. The company’s fifty day moving average is $277.12 and its 200 day moving average is $308.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the firm earned $4.96 earnings per share. The company’s revenue was up 23.2% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.54%. Amgen’s dividend payout ratio is presently 121.90%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.